The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt.

Levine; Daniel M.

Parker; Thomas S.

Gordon; Bruce R.

Saal; Stuart D.

Sepsicure, LLC

Method for treating sepsis in patients with albumin, cholesterol and HDL levels above minimum thresholds

Disclosed is a fusion protein Slit2D2-HSA formed by fusion of a Slit2D2 polypeptide and a human serum albumin HSA, and use thereof for the manufacture of a medicament for prophylaxis and/or treatment of sepsis, and the said fusion protein Slit2D2-HSA retains the pharmacological activities of Slit2 in inhibition of neutrophil migration and treatment of sepsis, and has an improved stability, prolonged half-life and improved therapeutic effect of sepsis. Compared with protein of Slit2, the polypeptide of Slit2D2 has a smaller molecular weight which is much easier to be purified and separated in preparation and used in the development of drugs.

Li; Huashun

ASCLEPIUS

TECHNOLOGY COMPANY GROUP CO., LTD.

Fusion protein SLIT2D2-HSA and its use in treatment of sepsis

A composition comprising Human Serum Albumin and an Amino Acid Solution, a method of making the same, and a method for use, including treating acute hypovolemia due to any number of medical conditions due to sepsis with shock, hemorrhagic shock, hypovolemic shock, burn injury, capillary leak syndrome, hypoalbuminemia, nephritic syndrome, or multi-organ failure with third space fluid loss from any other medical disease.

Blood replacement product

An extracorporeal circuit for removing toxins from the blood and plasma volume control in patients suffering from sepsis and renal failure. The extracorporeal circuit disclosed herein comprises a plasma filter, a toxin removal device and optionally a hemofilter that minimizes electrolyte and protein depletion from the treated plasma while effectively removing both free and protein-bound toxins. The toxin removal device comprises adsorbent materials selected from the group consisting of activated carbon, ion exchange resins and non-ionic exchange resins and the adsorbent materials are coated with albumin. Also provided are associated methods for treating patients suffering from sepsis and renal failure using the disclosed extracorporeal circuit and toxin removal device.

Hemolife Medical, Inc.

Plasma detoxification and volume control system and methods of use

The invention relates to a sorption agent for removing endotoxins from a biological fluid, comprising a water-insoluble, porous carrier having a neutral hydrophobic surface wherein the surface of the carrier has an adsorptive coating made of polymyxin and albumin, wherein polymyxin and albumin are bonded to the surface of the carrier in a noncovalent manner. The invention further relates to a method for producing such a sorption agent. The sorption agent is used in extracorporeal blood purification, in particular in order to treat individuals, who have sepsis.

sepsis/albumin

Method for treating sepsis in patients with albumin, cholesterol and HDL levels above minimum thresholds

Fusion protein SLIT2D2-HSA and its use in treatment of sepsis

Blood replacement product

Plasma detoxification and volume control system and methods of use

Sorbent for endotoxins

Baz done ki pi konplè remèd fèy medsin te apiye nan syans